Oct 02, 2023
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Sep 20, 2023
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Sep 05, 2023
Immutep to Participate in September Investor Conferences
Aug 01, 2023
Immutep Receives Positive Scientific Advice from European Medicines Agency
Jul 31, 2023
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023
